The UK government has unequivocally reiterated its firm stance that it holds "no plans" to introduce statutory menstrual leave for individuals diagnosed with endometriosis or adenomyosis. This consistent position comes despite a compelling public petition that garnered over 100,000 signatures, thereby mandating a parliamentary debate, which took place earlier this week. The debate, a significant moment for advocates of menstrual health awareness, brought into sharp focus the debilitating impact of these chronic conditions on millions and the ongoing call for more robust workplace support mechanisms.
The Campaign for Change: A National Petition Ignites Debate
The recent parliamentary discussion, held on April 13, 2026, was primarily driven by a powerful public petition initiated by campaigner Michelle Dewar. This petition, a testament to growing public awareness and demand for action, successfully surpassed the 100,000-signature threshold, compelling Members of Parliament to address the issue directly. At its core, the petition urged the UK government to implement a statutory menstrual leave policy, drawing inspiration from a progressive law recently enacted in Portugal. Such a policy, as envisioned by the petitioners, would grant individuals with a valid medical diagnosis up to three days of paid menstrual leave per month. Crucially, it also called for comprehensive employment protections, ensuring confidentiality and non-discrimination in the workplace for those affected.
The debate in the House of Commons was spearheaded by Paul Davis, the Labour MP for Colne Valley, whose personal connection to the issue added a poignant dimension to his advocacy. Davis revealed that his wife, Leah, had suffered from endometriosis into her 30s, providing him with firsthand insight into the profound challenges faced by those living with the condition. His impassioned plea underscored the urgent need for a more empathetic and structured approach to menstrual health within the national employment framework.
Understanding the Conditions: Endometriosis and Adenomyosis
To fully grasp the impetus behind the petition and the parliamentary debate, it is essential to understand the nature and severity of endometriosis and adenomyosis. These are chronic, often debilitating, gynaecological conditions that affect a significant portion of the female population.
Endometriosis occurs when tissue similar to the lining of the womb (the endometrium) grows outside the uterus. These growths, known as implants or lesions, can be found on organs such as the ovaries, fallopian tubes, the outer surface of the uterus, bowel, and bladder. Like the uterine lining, these ectopic tissues respond to hormonal fluctuations during the menstrual cycle, thickening, breaking down, and bleeding. However, unlike menstrual blood, this blood has no exit path from the body, leading to inflammation, pain, scar tissue formation, adhesions (where tissues stick together), and potentially cysts. Symptoms vary widely but commonly include severe pelvic pain, particularly during menstruation (dysmenorrhea), chronic pelvic pain, pain during or after sex (dyspareunia), heavy periods (menorrhagia), fatigue, and infertility. It is estimated that endometriosis affects approximately 1 in 10 women and people assigned female at birth globally, equating to around 1.5 million individuals in the UK alone. The average diagnosis time in the UK remains a concerning 7 to 8 years, a delay that often leads to prolonged suffering and progression of the disease.
Adenomyosis, often referred to as "internal endometriosis," is a related but distinct condition where endometrial tissue grows into the muscular wall of the uterus (the myometrium). This abnormal growth causes the uterine wall to thicken and enlarge, leading to similar symptoms as endometriosis, including severe, painful, and heavy periods, chronic pelvic pain, and abdominal bloating. While both conditions can coexist and share symptomatic overlaps, adenomyosis primarily affects the uterus itself, often resulting in a tender, enlarged uterus. The exact prevalence of adenomyosis is harder to ascertain definitively, partly due to diagnostic challenges, but studies suggest it affects between 20% and 65% of women, often co-occurring with endometriosis.
The chronic pain, heavy bleeding, and associated symptoms of both conditions can severely impact an individual’s quality of life, mental health, and ability to participate fully in daily activities, including work. Many sufferers report significant challenges with concentration, mobility, and energy levels, making traditional work environments particularly demanding during symptomatic flare-ups.
The Parliamentary Debate: Voices for Menstrual Health and Workplace Reform
During the debate, Paul Davis MP passionately articulated the need for a paradigm shift in how menstrual health, particularly conditions like endometriosis and adenomyosis, is perceived and managed in the workplace. He argued that the government’s existing "Keep Britain Working" workplace health reforms, while commendable, needed to explicitly incorporate and expand their focus to encompass menstrual health and women’s health more broadly.
"To challenge the stigma, we must strive to understand that endometriosis and adenomyosis are systemic, chronic health conditions that can derail somebody’s life," Davis asserted. He highlighted the pervasive lack of awareness surrounding these conditions, compounded by a deeply ingrained societal taboo surrounding menstrual health. This combination, he argued, "accentuates the suffering of patients, making them feel as though they have nowhere to turn and no shoulder to lean on."
Davis drew a compelling parallel with other chronic conditions that affect a similar demographic, such as Type 2 diabetes. He noted the "positive acceptance and understanding of the difficulties faced by those with Type 2 diabetes – and rightly so." He then urged Parliament to "replicate that acceptance and understanding in our attitude towards menstrual health," advocating for an environment where individuals feel comfortable and supported in discussing their symptoms without fear of judgment or professional repercussions.
Beyond the call for statutory leave, Davis presented several actionable proposals aimed at fostering more inclusive and supportive workplaces. He championed the expansion of Endometriosis UK’s "endometriosis-friendly employer" scheme, a laudable initiative that encourages businesses to adopt best practices for supporting employees with the condition. Furthermore, he proposed the establishment of a national workplace endometriosis and adenomyosis pledge, where businesses would formally commit to developing and implementing specific employer action plans. These plans would integrate "seemingly little things – such as toilet access, break rotations or even the size ranges of uniforms – into a national framework of practical workplace adjustments," which, he contended, "can greatly improve the workplace experience of menstrual health, including endometriosis and adenomyosis." Ultimately, Davis concluded, implementing a statutory leave policy would empower women with "the flexibility and legal right to have time off work when they are suffering most."
International Precedents: Portugal’s Groundbreaking Law and Global Context
The petition’s specific reference to Portugal highlights a growing international movement towards recognizing and legislating for menstrual leave. In February 2023, Portugal became the first European country to introduce a law granting up to three days of paid menstrual leave per month for individuals experiencing severe period pain, provided they have a medical certificate. This progressive legislation is part of a broader package of sexual and reproductive health rights, reflecting a commitment to destigmatizing menstruation and supporting women’s health. The Portuguese model specifically requires a medical diagnosis for eligibility, ensuring the policy targets those with genuinely debilitating conditions and is not broadly applied to general menstrual discomfort. It also explicitly includes provisions for confidentiality and non-discrimination, aiming to mitigate potential negative impacts on employment.
Portugal is not alone in this endeavour. Several other countries have various forms of menstrual leave policies, some dating back decades. Japan, for instance, introduced menstrual leave in 1947, allowing women to take time off if they experience severe pain. South Korea followed suit in 2001, providing unpaid menstrual leave. Indonesia has had a law since 2003 granting two days of paid leave per month for menstrual pain. More recently, Spain passed a similar law to Portugal in February 2023, making it the first Western European country to implement such a policy. Other nations, including Taiwan and Zambia, also have provisions for menstrual leave, albeit with varying conditions regarding pay, duration, and medical certification.
These international examples demonstrate a diverse range of approaches to menstrual leave, reflecting different cultural, economic, and legislative contexts. While the specific models differ, the underlying principle is a recognition that menstruation, particularly when complicated by conditions like endometriosis and adenomyosis, can significantly impair an individual’s ability to work effectively, and that traditional sick leave policies may not adequately address these specific, recurring health challenges.
The Government’s Unwavering Position and Broader Health Strategy
Despite the compelling arguments and international precedents, the UK government’s position on statutory menstrual leave has remained steadfastly unchanged. Responding to the petition last year, and reaffirming this stance after the recent debate, the government stated it had "no plans to introduce menstrual leave for those with endometriosis or adenomyosis." While acknowledging the "hardship they cause," the government has consistently pivoted to its existing and developing employment rights reforms and broader health strategies as the preferred mechanisms for managing health at work.
Responding for the government during the debate, employment rights minister Kate Dearden highlighted what she termed "strong progress" in translating the commitments outlined in the last government’s 2022 Women’s Health Strategy into tangible action. She indicated that a renewed strategy would be unveiled, designed to outline "how this Government will take further steps to improve women’s health as we deliver the 10-year health plan."
Dearden emphasized that this renewed strategy would specifically "address the gaps in the 2022 strategy, and go further to create a system that listens to women, tackles health inequalities and makes progress on conditions such as endometriosis." A key focus, she added, would be on identifying and removing "enduring barriers to high-quality care, such as those extremely long wait lists for diagnosis, and ensure that professionals listen and respond to women’s needs." The government’s approach, therefore, appears to prioritize improving healthcare access, diagnostic pathways, and general workplace health frameworks rather than introducing a specific, condition-based statutory leave policy.
Expert Analysis: Legal and Workplace Implications
The debate around statutory menstrual leave is complex, with a range of legal, HR, and societal implications that warrant careful consideration. Ben Smith, a partner in the employment team of law firm Charles Russell Speechlys, provided a nuanced perspective, acknowledging the sensitivity of the issue now brought into the spotlight.
From an employee’s viewpoint, Smith conceded that "the introduction of statutory leave may help people better manage chronic menstrual-related conditions without potentially losing out on pay." This could offer much-needed financial security and reduce the pressure on individuals to work through severe pain. However, he also raised a significant counterpoint: "some employees may say it actually increases the stigma associated with having the condition and they may not want to disclose such personal details to their employer." The fear of being perceived as less capable or reliable, or simply the discomfort of discussing intimate health matters, could lead to under-utilisation or increased anxiety.
Smith further delved into broader policy concerns, posing the critical question: "where do we draw the line?" He argued that if statutory leave is introduced for endometriosis and adenomyosis, "an argument could be made that introducing statutory leave for conditions like endometriosis and adenomyosis means we should also do so for every other chronic health condition." This, he suggested, "would likely put unbearable pressure on employers," raising concerns about the administrative burden, financial costs, and operational challenges for businesses, particularly small and medium-sized enterprises (SMEs).
Moreover, Smith cautioned against the potential for workplace resentment and discrimination. "Only introducing statutory leave for menstrual-related conditions has the potential to create resentment in the workplace," he stated, as employees with other chronic conditions might feel unfairly treated. He also highlighted a concerning risk for employers: "It could also increase the risk of discrimination in hiring and promotions amongst some employers worried about cost and dependability." This fear, whether conscious or unconscious, could lead to subtle biases against individuals perceived as more likely to require such leave.
In light of these complexities, Smith concluded that "rather than implementing a statutory menstrual leave, the priority in my view is to ensure more training, education, and awareness of menstrual-related conditions and the severe impact of associated symptoms so that employees can be better supported and there can be more flexibility and understanding in the workplace." This perspective aligns with many HR professionals who advocate for a more holistic approach focused on cultural change, reasonable adjustments, and flexible working policies, rather than a single, prescriptive leave entitlement.
Beyond Statutory Leave: Holistic Workplace Solutions
The discussions, both in Parliament and among legal and HR experts, underscore that while statutory leave is one proposed solution, a more comprehensive strategy for supporting individuals with endometriosis and adenomyosis in the workplace likely involves multiple interconnected approaches.
Central to this is the expansion and adoption of "endometriosis-friendly employer" schemes, such as the one championed by Endometriosis UK. These schemes typically involve training for managers and HR teams to increase understanding of the conditions, promoting open communication, and fostering a supportive culture where employees feel comfortable disclosing their health needs. Practical workplace adjustments, as mentioned by Paul Davis, are vital. These can include flexible working hours, the option to work from home, access to quiet spaces, adjustable workstations, regular breaks, and consideration for uniform comfort. Ensuring easy access to toilets and privacy facilities is also a frequently cited need for those managing heavy bleeding or frequent pain.
Furthermore, the role of occupational health services cannot be overstated. These services can provide confidential support, advise on reasonable adjustments, and facilitate communication between employees and employers, ensuring that individual needs are met while respecting privacy. Investing in education and awareness campaigns within organizations can help to destigmatize menstrual health issues, reducing the "taboo" that Paul Davis highlighted and creating a more inclusive environment for all employees.
The economic implications of these conditions are also substantial. Studies have shown that endometriosis alone costs the UK economy billions of pounds annually in lost productivity, healthcare costs, and reduced quality of life. Addressing these conditions effectively in the workplace is not just a matter of social justice but also an economic imperative. By fostering supportive environments, employers can reduce presenteeism (working while ill, often leading to reduced productivity), absenteeism, and staff turnover, ultimately benefiting both employees and the business.
The Road Ahead: Balancing Support and Practicalities
The debate surrounding statutory menstrual leave in the UK reflects a broader societal conversation about women’s health, workplace equity, and the evolving nature of employee support. While the government’s current stance remains firm against implementing a specific statutory leave policy, the parliamentary debate and the public petition have undeniably raised the profile of endometriosis and adenomyosis, compelling a national dialogue on their profound impact.
The path forward appears to involve a multi-pronged approach: continued advocacy for statutory recognition, alongside a concerted effort to enhance existing healthcare provisions, accelerate diagnosis times, and encourage employers to adopt more flexible, understanding, and "endometriosis-friendly" practices. The tension between providing specific, legally mandated leave and promoting broader, flexible workplace adjustments will likely continue to be a central theme. Ultimately, the goal remains to ensure that individuals living with these challenging conditions can manage their health effectively without compromising their careers or their fundamental right to a dignified and supportive working life. The conversation has started, and while immediate legislative change on menstrual leave may not be on the horizon, the pressure for systemic improvements in women’s health and workplace support will undoubtedly persist.
